Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jackson Liu

Pain Medicine Lancaster, PA Medical Doctor

NPI 1528200185 CMS profile 548990

170 N Pointe Blvd, Lancaster, PA 17601

Open in the dashboard

General payments

$3,310

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jackson Liu of Lancaster, PA is reported in the CMS Open Payments database as having received $3,310 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 10
2024 General $101 4
2023 General $244 5
2022 General $93 2
2021 General $1,365 4
2020 General $39 2
2019 General $692 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jackson Liu
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jackson Liu were reported at $777. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Jackson Liu Pain Medicine median Middle half National median
2019 $692 $409 $115–$1,311 $163
2020 $39 $214 $66–$666 $114
2021 $1,365 $299 $84–$899 $132
2022 $93 $335 $103–$1,149 $149
2023 $244 $376 $114–$1,228 $160
2024 $101 $387 $115–$1,173 $164
2025 $777 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,430 24 payments
  2. Novus Surgical Solutions LLC $1,200 1 payment
  3. Abbott Laboratories $431 9 payments
  4. Vertiflex, Inc. $116 2 payments
  5. Zimmer Biomet Holdings, Inc. $48 1 payment
  6. SI-BONE, Inc. $21 1 payment
  7. Stryker Corporation $19 1 payment
  8. Medtronic, Inc. $18 1 payment
  9. Vertos Medical, Inc. $14 1 payment
  10. Scilex Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,110 41 payments
  2. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. Infinion 16 $390 5 payments
  2. Intracept $250 4 payments
  3. INFINION Pain Management $249 3 payments
  4. General - Pain Management $202 2 payments
  5. PROCLAIM $131 1 payment
  6. Superion ISS $116 2 payments
  7. Proclaim Family of SCS IPGs $115 1 payment
  8. Proclaim IPG $106 2 payments
  9. WaveWriter Alpha Prime 16 $101 3 payments
  10. INFINION Pain Management $59 1 payment
  11. Other $268 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

205

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$1,012

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

14.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 74 $672
Tramadol Hcl Generic 73 $102
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $79
Methylprednisolone Generic 13 $74
Acetaminophen-Codeine Acetaminophen With Codeine Brand 11 $43
Cyclobenzaprine Hcl Generic 16 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$115,420

Of which drugs: $159

Medicare patients

359

Average age 75

Services billed

1,528

229 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 23%
Depression 22%
Cancer 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 47 226 $159

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record